What is Sutro Biopharma's restricted cash?

Sutro Biopharma (STRO) reported restricted cash of $858K in Q1 2026.

How has Sutro Biopharma's restricted cash changed year-over-year?

Sutro Biopharma's restricted cash decreased by 0.0% year-over-year, from $858K to $858K.

What is the long-term trend for Sutro Biopharma's restricted cash?

Over 5 years (2020 to 2025), Sutro Biopharma's restricted cash has grown at a -0.3% compound annual growth rate (CAGR), from $872K to $858K.

What does restricted cash mean?

Cash restricted for specific purposes by contractual, regulatory, or legal requirements — not available for general corporate use.

Sutro Biopharma STRO Restricted Cash

Restricted Cash at other companies

RegenxbioRGNX

$2.03M0.0%

XencorXNCR

$191K-32.7%

SchrodingerSDGR

$7.46M-36.6%

CytomX TherapeuticsCTMX

$1.53M+48.5%

Stoke Therapeutics, Inc.STOK

$3.23M+4,203%

Roivant SciencesROIV

——

Other financials

Income statement

See full

Revenue$14.5M-16.5%

Operating income-$29.7M+56.7%

Net income-$38.5M+49.3%

EPS (diluted)-$2.94+67.6%

Balance sheet

See full

Cash & equivalents$73.7M-30.6%

Total debt$13.6M-36.3%

Total equity-$66.9M-159%

Total assets$242.0M-24.7%

Cash flow

See full

Operating cash flow-$42.3M+37.7%

CapEx--100%

Free cash flow-$42.3M+37.8%

Valuation

See full

Market cap$489.66M+624%

Enterprise value$429.61M-2,600%

P/S4.9×+3.9×

Profitability

See full

Operating margin-120%-48.6pp

Net margin-154.2%-56.7pp

FCF margin-152.2%-51.1pp

Returns & leverage

See full

Return on equity-234.2%—

Debt / equity0.5×+0.3×

Current ratio3.1×+1.0×

Where this comes from

Reported directly by Sutro Biopharma in its filing.

Tagged under the XBRL concept us-gaap:RestrictedCashNoncurrent.

The official record: Sutro Biopharma’s 10-Q, filed May 14, 2026, on SEC EDGAR. View the filing →

Ask your AI about Sutro Biopharma's restricted cash.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Sutro Biopharma's restricted cash?: Sutro Biopharma (STRO) reported restricted cash of $858K in Q1 2026.
How has Sutro Biopharma's restricted cash changed year-over-year?: Sutro Biopharma's restricted cash decreased by 0.0% year-over-year, from $858K to $858K.
What is the long-term trend for Sutro Biopharma's restricted cash?: Over 5 years (2020 to 2025), Sutro Biopharma's restricted cash has grown at a -0.3% compound annual growth rate (CAGR), from $872K to $858K.
What does restricted cash mean?: Cash restricted for specific purposes by contractual, regulatory, or legal requirements — not available for general corporate use.